Molecular Targeted Therapies in T-Cell Acute Lymphoblastic Leukemia

[1]  L. Chin,et al.  High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. , 2009, Blood.

[2]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[3]  A. Sirvent,et al.  Cytoplasmic signalling by the c‐Abl tyrosine kinase in normal and cancer cells , 2008, Biology of the cell.

[4]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[5]  T. Golde,et al.  Rational targeting of Notch signaling in cancer , 2008, Oncogene.

[6]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[7]  D. Gilliland,et al.  Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies , 2008, Leukemia.

[8]  M. Varella‐Garcia,et al.  Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation , 2008, Nature.

[9]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[10]  G. Verdine,et al.  The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members , 2007, Clinical Cancer Research.

[11]  A. Look,et al.  NOTCH and PI3K-AKT pathways intertwined. , 2007, Cancer cell.

[12]  Govind Bhagat,et al.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.

[13]  G. Mills,et al.  A new mutational AKTivation in the PI3K pathway. , 2007, Cancer cell.

[14]  A. Ferrando,et al.  The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia , 2007, The Journal of experimental medicine.

[15]  Rob Pieters,et al.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.

[16]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[17]  L. Chin,et al.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers , 2007, Nature.

[18]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[19]  Adam A. Margolin,et al.  NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth , 2006, Proceedings of the National Academy of Sciences.

[20]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[21]  S. Baker,et al.  PTEN function in normal and neoplastic growth. , 2006, Cancer letters.

[22]  M. Bhasin,et al.  Notch1 Contributes to Mouse T-Cell Leukemia by Directly Inducing the Expression of c-myc , 2006, Molecular and Cellular Biology.

[23]  S. Bray.  Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.

[24]  J. Aster,et al.  c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. , 2006, Genes & development.

[25]  J. Aster,et al.  A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[27]  A. Look,et al.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia , 2006, Nature Reviews Cancer.

[28]  W. Pear,et al.  Notch-dependent T-lineage commitment occurs at extrathymic sites following bone marrow transplantation. , 2006, Blood.

[29]  Jen-Fen Fu,et al.  K‐ras mutations and N‐ras mutations in childhood acute leukemias with or without mixed‐lineage leukemia gene rearrangements , 2006, Cancer.

[30]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[31]  S. Perkins,et al.  Childhood and adolescent non‐Hodgkin lymphoma: New insights in biology and critical challenges for the future , 2005, Pediatric blood & cancer.

[32]  R. Zappatore,et al.  ABL1 amplification in T-cell acute lymphoblastic leukemia. , 2005, Cancer genetics and cytogenetics.

[33]  L. Hooper.  Faculty Opinions recommendation of Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. , 2005 .

[34]  Peter Marynen,et al.  Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). , 2005, Blood.

[35]  Francois Pognan,et al.  Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[37]  W. Pear,et al.  Notch and T cell malignancy. , 2004, Seminars in cancer biology.

[38]  A. Ferrando,et al.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia , 2004, Nature Genetics.

[39]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[40]  X. Shu,et al.  RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia , 2004, Leukemia.

[41]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.

[42]  A. Ferrando,et al.  Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. , 2004, Blood.

[43]  Eric C. Lai,et al.  Notch signaling: control of cell communication and cell fate , 2004, Development.

[44]  Freddy Radtke,et al.  Notch regulation of lymphocyte development and function , 2004, Nature Immunology.

[45]  A. Ferrando,et al.  Gene expression profiling in T-cell acute lymphoblastic leukemia. , 2003, Seminars in hematology.

[46]  F. Papavasiliou,et al.  V(D)J Recombination and the Evolution of the Adaptive Immune System , 2003, PLoS biology.

[47]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[48]  H C Clevers,et al.  Transcriptional Control of T Lymphocyte Differentiation , 2001, Stem cells.

[49]  J. Sklar,et al.  TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.

[50]  E. Reinherz,et al.  Current concepts in immunology: Regulation of the immune response--inducer and suppressor T-lymphocyte subsets in human beings. , 1980, The New England journal of medicine.

[51]  R. Punnett,et al.  The Theory of the Gene , 1926, Nature.

[52]  Thomas Hunt Morgan,et al.  The Theory of the Gene , 1917, The American Naturalist.

[53]  Iannis Aifantis,et al.  γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia , 2009, Nature Medicine.

[54]  Ellen V Rothenberg,et al.  Molecular genetics of T cell development. , 2005, Annual review of immunology.

[55]  S. Armstrong,et al.  Molecular genetics of acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Higgins,et al.  Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. , 2004, The Journal of biological chemistry.

[57]  A L Hopkins,et al.  Target analysis: a priori assessment of druggability. , 2003, Ernst Schering Research Foundation workshop.